Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Metadata listed "SOLESENCE, INC." but filing text confirms Nanophase Technologies Corporation).
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2000.
Business Overview: The Company develops and sells nanocrystalline materials for commercial production. Since its inception in 1989, the Company has incurred cumulative losses and funded operations primarily through equity issuances. Revenue is generated from product sales, development arrangements, and licensing, with major customers in healthcare and electronics markets.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenue | $1,105,336 | $1,724,257 |
| Net Loss | $(1,252,767) | $(2,687,326) |
| Net Loss Per Share | $(0.09) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $504,781 | |
| Total Investments | $18,785,372 | |
| Net Cash Used in Operating Activities | $(3,367,472) (Six Months) | |
| Accumulated Deficit | $(27,182,944) |
Liquidity: Total cash, cash equivalents, and investments amounted to $19,290,153 as of June 30, 2000. The Company reports no long-term debt on the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly compared to the prior year. For the six months ended June 30, 2000, revenue rose to $1,724,257 from $654,219 in 1999. Product revenue specifically increased to $1,488,007 from $547,302.
- Operating Expenses: Cost of revenue increased to $2,123,985 (six months) from $1,461,884, driven by increased product shipments. Research and development expenses rose to $1,042,612 from $784,722 due to new personnel and development activities.
- SG&A Reduction: Selling, general, and administrative expenses decreased to $1,827,725 from $2,142,205, primarily due to reduced legal expenses and executive compensation.
- Net Loss Improvement: Despite higher operating costs, the net loss for the six months ended June 30, 2000, was $(2,687,326), an improvement from $(3,157,935) in the prior year period, aided by increased interest income.
Guidance, Outlook, Risks, and Contingencies
Outlook: Management expects to further increase research and development expenses for the remainder of 2000 to expand product lines. The Company believes current cash and investment proceeds are adequate to fund current operating plans but may seek additional funding in the future, which could be dilutive.
Legal Contingencies:
- Consolidated Complaint (IPO Litigation): The Company reached an oral agreement in principle to settle claims related to its initial public offering for $4,025,000. The settlement is expected to be funded primarily by directors and officers liability insurance and is not considered to have a material adverse effect on financial position.
- Preferred Stockholders' Complaint: A separate complaint regarding the solicitation of consents for the IPO remains pending. The Company intends to defend vigorously, though the outcome is unpredictable.
Risks: Key risks include uncertain demand for nanocrystalline materials, dependence on a limited number of key customers, limited manufacturing capacity, and the resolution of ongoing litigation.
Investor Verification Checklist
- Settlement Finalization: Verify the status of the $4,025,000 litigation settlement and confirm the extent of insurance coverage versus potential out-of-pocket costs.
- Revenue Quality: Assess the concentration of revenue among key customers in the healthcare and electronics sectors to evaluate dependency risks.
- Cash Burn Rate: Monitor the net cash used in operating activities ($3.37M for six months) against the current cash and investment balance ($19.3M) to determine runway without additional financing.
- Inventory Valuation: Review the allowance for excess inventory quantities ($189,366) and the increase in raw materials and finished goods.
- Future Capital Needs: Evaluate the likelihood of dilutive equity financing given the Company's history of funding operations through stock issuance and its accumulated deficit.